Low Dose Rate Brachytherapy Boost for High-risk Prostate Cancer: An Evidence-based Approach

Madam — This letter is a response to the recent overview on high dose rate (HDR) brachytherapy in high-risk localised disease in the prostate cancer special issue by Morton and Alrashidi [1].

Source: Clinical Oncology - April 7, 2020 Category: Radiology Authors: C. Mikropoulos, S. Otter, C. Perna, S. Khaksar, A. Franklin, R. Laing, J. Uribe, S.U. Lewis, S. Langley Tags: Letter Source Type: research